All Stories

  1. Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma

    Article • Blood, September 2024, American Society of Hematology

    Dr Albert Oriol

  2. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

    Article • Nature Genetics, August 2024, Springer Science + Business Media

    Dr Albert Oriol

  3. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2024, New England Journal of Medicine (NEJM/MMS)

    Dr Albert Oriol

  4. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Article • Journal of Clinical Oncology, July 2024, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  5. Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial

    Article • Haematologica, July 2024, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  6. Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial

    Article • The Lancet Haematology, July 2024, Elsevier

    Dr Albert Oriol

  7. Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study

    Article • Clinical Lymphoma Myeloma & Leukemia, May 2024, Elsevier

    Dr Albert Oriol

  8. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Article • Blood Cancer Journal, April 2024, Springer Science + Business Media

    Dr Albert Oriol

  9. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

    Article • Cancer, April 2024, Wiley

    Dr Albert Oriol

  10. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study

    Article • Leukemia & Lymphoma, March 2024, Taylor & Francis

    Dr Albert Oriol

  11. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Article • Clinical Lymphoma Myeloma & Leukemia, March 2024, Elsevier

    Dr Albert Oriol

  12. CD200 genotype is associated with clinical outcome of patients with multiple myeloma

    Article • Frontiers in Immunology, February 2024, Frontiers

    Dr Albert Oriol

  13. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Article • Haematologica, February 2024, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  14. Predictors of unsustained measurable residual disease negativity in transplant-eligible multiple myeloma patients

    Article • Blood, December 2023, American Society of Hematology

    Dr Albert Oriol

  15. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Article • Haematologica, November 2023, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  16. Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational Study

    Article • Cancers, November 2023, MDPI AG

    Dr Albert Oriol

  17. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

    Article • Frontiers in Oncology, November 2023, Frontiers

    Dr Albert Oriol

  18. Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment

    Article • Clinical Lymphoma Myeloma & Leukemia, November 2023, Elsevier

    Dr Albert Oriol

  19. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

    Article • The Lancet Haematology, October 2023, Elsevier

    Dr Albert Oriol

  20. Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

    Article • Blood Cancer Journal, September 2023, Springer Science + Business Media

    Dr Albert Oriol

  21. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Article • Nature Communications, September 2023, Springer Science + Business Media

    Dr Albert Oriol

  22. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2023, New England Journal of Medicine (NEJM/MMS)

    Dr Albert Oriol

  23. Impact of Prolonged Ischemia on the Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1)

    Article • Applied Immunohistochemistry & Molecular Morphology, September 2023, Wolters Kluwer Health

    Dr Albert Oriol

  24. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

    Article • Haematologica, August 2023, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  25. LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED BY RESIDUAL DISEASE STATUS IN MYELOMA

    Article • Blood, July 2023, American Society of Hematology

    Dr Albert Oriol

  26. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 2023, New England Journal of Medicine (NEJM/MMS)

    Dr Albert Oriol

  27. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma

    Article • Future Oncology, July 2023, Taylor & Francis

    Dr Albert Oriol

  28. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies

    Article • Journal of Clinical Oncology, June 2023, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  29. First-line treatment of multiple myeloma in both transplant and non-transplant candidates

    Article • Expert Review of Anticancer Therapy, May 2023, Taylor & Francis

    Dr Albert Oriol

  30. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

    Article • Blood Cancer Journal, May 2023, Springer Science + Business Media

    Dr Albert Oriol

  31. Randomized phase II study of weekly carfilzomib 70 mg/m<sup>2</sup> and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

    Article • Haematologica, April 2023, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  32. Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

    Article • Frontiers in Immunology, April 2023, Frontiers

    Dr Albert Oriol

  33. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

    Article • Future Oncology, April 2023, Taylor & Francis

    Dr Albert Oriol

  34. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

    Article • Blood Cancer Journal, March 2023, Springer Science + Business Media

    Dr Albert Oriol

  35. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

    Article • Journal of Clinical Oncology, January 2023, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  36. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

    Article • Leukemia & Lymphoma, January 2023, Taylor & Francis

    Dr Albert Oriol

  37. Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2022, New England Journal of Medicine (NEJM/MMS)

    Dr Albert Oriol

  38. Optimization of monocyte gating to quantify monocyte subsets for the diagnosis of chronic myelomonocytic leukemia

    Article • Cytometry Part B Clinical Cytometry, November 2022, Wiley

    Dr Albert Oriol

  39. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

    Article • The Lancet Haematology, November 2022, Elsevier

    Dr Albert Oriol

  40. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Article • Cancers, October 2022, MDPI AG

    Dr Albert Oriol

  41. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

    Article • European Journal of Cancer, October 2022, Elsevier

    Dr Albert Oriol

  42. MM-071 Subcutaneous (SC) Isatuximab (Isa) Administration by an On-Body Delivery System (OBDS) in Combination With Pomalidomide-Dexamethasone (Pd) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients: Interim Phase 1b Study Results

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2022, Elsevier

    Dr Albert Oriol

  43. Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    Article • Cancer Medicine, September 2022, Wiley

    Dr Albert Oriol

  44. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Article • Clinical Cancer Research, September 2022, American Association for Cancer Research (AACR)

    Dr Albert Oriol

  45. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2022, Elsevier

    Dr Albert Oriol

  46. Teclistamab in Relapsed or Refractory Multiple Myeloma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2022, New England Journal of Medicine (NEJM/MMS)

    Dr Albert Oriol

  47. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis

    Article • European Journal Of Haematology, July 2022, Wiley

    Dr Albert Oriol

  48. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis

    Article • Hematological Oncology, June 2022, Wiley

    Dr Albert Oriol

  49. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Article • Journal of Clinical Oncology, June 2022, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  50. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    Article • The Lancet Haematology, June 2022, Elsevier

    Dr Albert Oriol

  51. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Article • Blood Cancer Journal, April 2022, Springer Science + Business Media

    Dr Albert Oriol

  52. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group

    Article • Blood Cancer Journal, April 2022, Springer Science + Business Media

    Dr Albert Oriol

  53. Corrigendum to P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [Clinical Lymphoma Myeloma an...

    Article • Clinical Lymphoma Myeloma & Leukemia, April 2022, Elsevier

    Dr Albert Oriol

  54. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma

    Article • American Journal of Hematology, March 2022, Wiley

    Dr Albert Oriol

  55. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

    Article • Blood Advances, February 2022, American Society of Hematology

    Dr Albert Oriol

  56. Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial

    Article • American Journal of Hematology, February 2022, Wiley

    Dr Albert Oriol

  57. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

    Article • The Lancet Haematology, February 2022, Elsevier

    Dr Albert Oriol

  58. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

    Article • Clinical Cancer Research, January 2022, American Association for Cancer Research (AACR)

    Dr Albert Oriol

  59. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

    Article • The Lancet Oncology, January 2022, Elsevier

    Dr Albert Oriol

  60. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Article • Blood, October 2021, American Society of Hematology

    Dr Albert Oriol

  61. Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

    Article • British Journal of Haematology, October 2021, Wiley

    Dr Albert Oriol

  62. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

    Article • European Journal Of Haematology, September 2021, Wiley

    Dr Albert Oriol

  63. Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma

    Article • Bone Marrow Transplantation, August 2021, Springer Science + Business Media

    Dr Albert Oriol

  64. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial

    Article • Clinical Cancer Research, August 2021, American Association for Cancer Research (AACR)

    Dr Albert Oriol

  65. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

    Article • The Lancet, August 2021, Elsevier

    Dr Albert Oriol

  66. Validation of the IMWG standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

    Article • Blood, July 2021, American Society of Hematology

    Dr Albert Oriol

  67. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    Article • The Lancet Oncology, June 2021, Elsevier

    Dr Albert Oriol

  68. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

    Article • The Lancet, June 2021, Elsevier

    Dr Albert Oriol

  69. Dose intensity and treatment duration of bortezomib in transplant‐ineligible newly diagnosed multiple myeloma

    Article • European Journal Of Haematology, May 2021, Wiley

    Dr Albert Oriol

  70. Current and Novel Alkylators in Multiple Myeloma

    Article • Cancers, May 2021, MDPI AG

    Dr Albert Oriol

  71. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Article • Blood Cancer Journal, May 2021, Springer Science + Business Media

    Dr Albert Oriol

  72. Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

    Article • British Journal of Haematology, April 2021, Wiley

    Dr Albert Oriol

  73. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2021, New England Journal of Medicine (NEJM/MMS)

    Dr Albert Oriol

  74. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

    Article • Blood, January 2021, American Society of Hematology

    Dr Albert Oriol

  75. Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma

    Article • Clinical Lymphoma Myeloma & Leukemia, January 2021, Elsevier

    Dr Albert Oriol

  76. The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma

    Article • Therapeutic Advances in Hematology, January 2021, SAGE Publications

    Dr Albert Oriol

  77. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

    Article • Journal of Clinical Oncology, December 2020, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  78. Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma

    Article • Blood Advances, December 2020, American Society of Hematology

    Dr Albert Oriol

  79. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial

    Article • Blood Advances, December 2020, American Society of Hematology

    Dr Albert Oriol

  80. Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

    Article • Cancers, December 2020, MDPI AG

    Dr Albert Oriol

  81. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

    Article • Journal of Clinical Oncology, December 2020, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  82. An RCT of Rapid Genomic Sequencing among Seriously Ill Infants Results in High Clinical Utility, Changes in Management, and Low Perceived Harm

    Article • The American Journal of Human Genetics, November 2020, Elsevier

    Dr Albert Oriol

  83. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

    Article • Blood Cancer Journal, November 2020, Springer Science + Business Media

    Dr Albert Oriol

  84. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

    Article • Leukemia & Lymphoma, October 2020, Taylor & Francis

    Dr Albert Oriol

  85. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Article • Blood Cancer Journal, October 2020, Springer Science + Business Media

    Dr Albert Oriol

  86. Melflufen for relapsed and refractory multiple myeloma

    Article • Expert Opinion on Investigational Drugs, September 2020, Taylor & Francis

    Dr Albert Oriol

  87. Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma

    Article • Leukemia & Lymphoma, September 2020, Taylor & Francis

    Dr Albert Oriol

  88. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Article • Blood, July 2020, American Society of Hematology

    Dr Albert Oriol

  89. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Article • Blood, June 2020, American Society of Hematology

    Dr Albert Oriol

  90. Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group

    Article • British Journal of Haematology, June 2020, Wiley

    Dr Albert Oriol

  91. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

    Article • Haematologica, April 2020, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  92. A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma

    Article • Expert Review of Hematology, March 2020, Taylor & Francis

    Dr Albert Oriol

  93. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

    Article • Leukemia, March 2020, Springer Science + Business Media

    Dr Albert Oriol

  94. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Article • Journal of Clinical Oncology, March 2020, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  95. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    Article • European Journal Of Haematology, March 2020, Wiley

    Dr Albert Oriol

  96. The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation

    Article • Applied Immunohistochemistry & Molecular Morphology, March 2020, Wolters Kluwer Health

    Dr Albert Oriol

  97. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses

    Article • Advances in Therapy, February 2020, Springer Science + Business Media

    Dr Albert Oriol

  98. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Article • Blood Cancer Journal, February 2020, Springer Science + Business Media

    Dr Albert Oriol

  99. Limited treatment options in refractory multiple myeloma: promising therapeutic developments

    Article • Expert Review of Anticancer Therapy, December 2019, Taylor & Francis

    Dr Albert Oriol

  100. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

    Article • Leukemia & Lymphoma, October 2019, Taylor & Francis

    Dr Albert Oriol, Zsolt Szabo

  101. A Randomized, Controlled Trial of the Analytic and Diagnostic Performance of Singleton and Trio, Rapid Genome and Exome Sequencing in Ill Infants

    Article • The American Journal of Human Genetics, October 2019, Elsevier

    Dr Albert Oriol

  102. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma

    Article • Blood, September 2019, American Society of Hematology

    Dr Albert Oriol

  103. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

    Article • The Lancet Haematology, September 2019, Elsevier

    Dr Albert Oriol

  104. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    Article • The Lancet Haematology, September 2019, Elsevier

    Dr Albert Oriol

  105. Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2019, Elsevier

    Dr Albert Oriol

  106. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

    Article • Clinical Lymphoma Myeloma & Leukemia, August 2019, Elsevier

    Dr Albert Oriol

  107. Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma

    Article • Blood, July 2019, American Society of Hematology

    Dr Albert Oriol

  108. Role of urine immunofixation in defining CR in MM

    Article • Blood, June 2019, American Society of Hematology

    Dr Albert Oriol

  109. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    Article • The Lancet Oncology, June 2019, Elsevier

    Dr Albert Oriol

  110. Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

    Article • Blood, May 2019, American Society of Hematology

    Dr Albert Oriol

  111. Diagnosis of genetic diseases in seriously ill children by rapid whole-genome sequencing and automated phenotyping and interpretation

    Article • Science Translational Medicine, April 2019, American Association for the Advancement of Science

    Dr Albert Oriol

  112. Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease

    Article • Blood, April 2019, American Society of Hematology

    Dr Albert Oriol

  113. Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma

    Article • Clinical Cancer Research, March 2019, American Association for Cancer Research (AACR)

    Dr Albert Oriol

  114. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

    Article • Blood Cancer Journal, March 2019, Springer Science + Business Media

    Dr Albert Oriol

  115. Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

    Article • Leukemia, March 2019, Springer Science + Business Media

    Dr Albert Oriol

  116. Pomalidomide‐dexamethasone for treatment of soft‐tissue plasmacytomas in patients with relapsed / refractory multiple myeloma

    Article • European Journal Of Haematology, February 2019, Wiley

    Dr Albert Oriol

  117. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

    Article • The Lancet, January 2019, Elsevier

    Dr Albert Oriol

  118. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Article • Leukemia, December 2018, Springer Science + Business Media

    Dr Albert Oriol

  119. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

    Article • Haematologica, September 2018, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  120. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

    Article • PLoS ONE, September 2018, PLOS

    Dr Albert Oriol

  121. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing

    Article • Haematologica, June 2018, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  122. A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility

    Article • Haematologica, March 2018, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  123. Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial

    Article • American Journal of Hematology, February 2018, Wiley

    Prof Agnieszka Wierzbowska, Dr Albert Oriol

  124. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

    Article • Leukemia, February 2018, Springer Science + Business Media

    Dr Albert Oriol

  125. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2018, New England Journal of Medicine (NEJM/MMS)

    Dr Albert Oriol

  126. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

    Article • Blood, January 2018, American Society of Hematology

    Dr Albert Oriol

  127. Long-Term Follow-Up of the Gem2010 Trial of Bortezomib-Melphalan-Prednisone and Lenalidomide-Dexamethasone in Elderly, Newly Diagnosed Multiple Myeloma Patients: Impact of Age, High-Risk Cytogenetics and Minimal Residual Disease

    Article • SSRN Electronic Journal, January 2018, Elsevier

    Dr Albert Oriol

  128. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low‐Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison

    Article • The Oncologist, November 2017, Alphamed Press

    Dr Albert Oriol

  129. Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials

    Article • Leukemia, November 2017, Springer Science + Business Media

    Dr Albert Oriol

  130. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

    Article • The Lancet Oncology, October 2017, Elsevier

    Dr Albert Oriol

  131. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

    Article • Journal of Clinical Oncology, September 2017, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  132. Segundas neoplasias en pacientes adultos receptores de un trasplante de progenitores hematopoyéticos

    Article • Medicina Clínica, September 2017, Elsevier

    Dr Albert Oriol

  133. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

    Article • European Journal Of Haematology, June 2017, Wiley

    Dr Albert Oriol

  134. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    Article • Leukemia, May 2017, Nature

    Dr Albert Oriol

  135. Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

    Article • Blood Cancer Journal, April 2017, Springer Science + Business Media

    Dr Albert Oriol

  136. Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma

    Article • European Journal Of Haematology, March 2017, Wiley

    Dr Albert Oriol

  137. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

    Article • Leukemia & Lymphoma, March 2017, Taylor & Francis

    Dr Albert Oriol

  138. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

    Article • British Journal of Haematology, February 2017, Wiley

    TAMAS DR MASSZI, Dr Albert Oriol

  139. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

    Article • Leukemia, February 2017, Nature

    Dr Albert Oriol

  140. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

    Article • The Lancet Oncology, February 2017, Elsevier

    Dr Albert Oriol

  141. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

    Article • Leukemia, January 2017, Nature

    Dr Albert Oriol

  142. Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial

    Article • Annals of Hematology, January 2017, Springer Science + Business Media

    Dr Albert Oriol

  143. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

    Article • Journal of Molecular Diagnostics, January 2017, Elsevier

    Dr Albert Oriol

  144. Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

    Article • Leukemia, December 2016, Nature

    Dr Albert Oriol

  145. Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

    Article • British Journal of Haematology, December 2016, Wiley

    Dr Albert Oriol

  146. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

    Article • Journal of Clinical Oncology, November 2016, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  147. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials

    Article • Annals of Hematology, October 2016, Springer Science + Business Media

    Dr Albert Oriol

  148. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, October 2016, New England Journal of Medicine (NEJM/MMS)

    Dr Albert Oriol

  149. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

    Article • Hematological Oncology, September 2016, Wiley

    Dr Albert Oriol

  150. Differentiation stage of myeloma plasma cells: biological and clinical significance

    Article • Leukemia, August 2016, Nature

    Dr Albert Oriol

  151. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

    Article • The Lancet Oncology, August 2016, Elsevier

    Dr Albert Oriol

  152. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

    Article • Blood, July 2016, American Society of Hematology

    Dr Albert Oriol

  153. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma

    Article • British Journal of Haematology, July 2016, Wiley

    Dr Albert Oriol

  154. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

    Article • Leukemia, July 2016, Nature

    Dr Albert Oriol

  155. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

    Article • Leukemia, June 2016, Nature

    Dr Albert Oriol

  156. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

    Article • Blood, May 2016, American Society of Hematology

    Dr Albert Oriol

  157. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

    Article • Blood, April 2016, American Society of Hematology

    Dr Albert Oriol

  158. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

    Article • Haematologica, April 2016, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  159. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

    Article • Blood, April 2016, American Society of Hematology

    Dr Albert Oriol

  160. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

    Article • The Lancet, April 2016, Elsevier

    Dr Albert Oriol

  161. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group

    Article • Leukemia Research, February 2016, Elsevier

    Dr Albert Oriol

  162. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance

    Article • Blood, January 2016, American Society of Hematology

    Dr Albert Oriol

  163. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Article • The Lancet Oncology, January 2016, Elsevier

    Dr ALESSANDRO Gozzetti, Dr Albert Oriol

  164. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

    Article • Acta Haematologica, January 2016, Karger Publishers

    Dr Albert Oriol

  165. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis

    Article • Blood, December 2015, American Society of Hematology

    Dr Albert Oriol

  166. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

    Article • Blood, October 2015, American Society of Hematology

    Dr Albert Oriol

  167. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale

    Article • Journal of Geriatric Oncology, September 2015, Elsevier

    Dr Albert Oriol

  168. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

    Article • Haematologica, August 2015, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  169. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

    Article • Haematologica, July 2015, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  170. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study

    Article • Haematologica, July 2015, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  171. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality

    Article • Blood, June 2015, American Society of Hematology

    Dr Albert Oriol

  172. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial

    Article • Haematologica, June 2015, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  173. Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma

    Article • British Journal of Haematology, June 2015, Wiley

    Dr Albert Oriol

  174. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

    Article • British Journal of Haematology, May 2015, Wiley

    Dr Albert Oriol

  175. Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial

    Article • Haematologica, April 2015, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  176. Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older

    Article • European Journal Of Haematology, March 2015, Wiley

    Dr Albert Oriol

  177. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2015, New England Journal of Medicine (NEJM/MMS)

    Dr Albert Oriol

  178. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

    Article • Leukemia Research Reports, January 2015, Elsevier

    Dr Albert Oriol

  179. Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study

    Article • Hematology, December 2014, Taylor & Francis

    Dr Albert Oriol

  180. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

    Article • British Journal of Haematology, November 2014, Wiley

    Dr Albert Oriol

  181. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Article • Leukemia, November 2014, Nature

    Dr Albert Oriol

  182. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2014, New England Journal of Medicine (NEJM/MMS)

    Dr Albert Oriol

  183. Nuevos fármacos en el tratamiento del mieloma múltiple

    Article • Medicina Clínica, September 2014, Elsevier

    Dr Albert Oriol

  184. Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Adult Patients

    Article • Acta Haematologica, August 2014, Karger Publishers

    Dr Albert Oriol

  185. A new prognostic score for AIDS-related lymphomas in the rituximab-era

    Article • Haematologica, August 2014, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  186. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

    Article • Blood, August 2014, American Society of Hematology

    Dr Albert Oriol

  187. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma

    Article • European Journal Of Haematology, June 2014, Wiley

    Dr Albert Oriol

  188. Pomalidomide in the treatment of multiple myeloma and perspectives in other hematological malignancies

    Article • International Journal of Hematologic Oncology, June 2014, Future Medicine

    Dr Albert Oriol

  189. Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHE...

    Article • Journal of Clinical Oncology, May 2014, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  190. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies

    Article • Haematologica, May 2014, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  191. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

    Article • Haematologica, April 2014, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  192. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Article • Blood, March 2014, American Society of Hematology

    Dr Albert Oriol

  193. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients

    Article • Leukemia & Lymphoma, February 2014, Taylor & Francis

    Dr Albert Oriol

  194. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

    Article • American Journal of Hematology, February 2014, Wiley

    Dr Albert Oriol

  195. Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia

    Article • Annals of Hematology, October 2013, Springer Science + Business Media

    Dr Albert Oriol

  196. Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

    Article • Leukemia, October 2013, Nature

    Dr Albert Oriol

  197. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Article • The Lancet Oncology, October 2013, Elsevier

    Dr Albert Oriol

  198. Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment

    Article • Nuclear Medicine Communications, October 2013, Wolters Kluwer Health

    Dr Albert Oriol

  199. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients

    Article • Blood, September 2013, American Society of Hematology

    Dr Albert Oriol

  200. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

    Article • British Journal of Haematology, August 2013, Wiley

    Dr Albert Oriol

  201. Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2013, New England Journal of Medicine (NEJM/MMS)

    Dr Albert Oriol

  202. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

    Article • Leukemia, July 2013, Nature

    Dr Albert Oriol

  203. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

    Article • Leukemia, June 2013, Nature

    Dr Albert Oriol

  204. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

    Article • Haematologica, February 2013, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  205. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status

    Article • Cancer, January 2013, Wiley

    Dr Albert Oriol

  206. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis

    Article • Blood, January 2013, American Society of Hematology

    Dr Albert Oriol

  207. Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials

    Article • American Journal Of Pathology, November 2012, Elsevier

    Dr Albert Oriol

  208. Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols

    Article • British Journal of Haematology, September 2012, Wiley

    Dr Albert Oriol

  209. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    Article • Blood, August 2012, American Society of Hematology

    Dr Albert Oriol

  210. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    Article • Journal of Clinical Oncology, July 2012, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  211. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

    Article • Blood, July 2012, American Society of Hematology

    Dr Albert Oriol

  212. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status

    Article • Leukemia, May 2012, Nature

    Dr Albert Oriol

  213. Carcinoma de células renales y mieloma múltiple: asociación sincrónica con posible patogenia inmunológica

    Article • Medicina Clínica, March 2012, Elsevier

    Dr Albert Oriol

  214. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience

    Article • Leukemia & Lymphoma, March 2012, Taylor & Francis

    Dr Albert Oriol

  215. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Article • Leukemia, February 2012, Nature

    Dr Albert Oriol

  216. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Article • Blood, November 2011, American Society of Hematology

    Dr Albert Oriol

  217. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease

    Article • Haematologica, November 2011, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  218. Multiple myeloma with extramedullary disease

    Article • Advances in Therapy, November 2011, Springer Science + Business Media

    Dr Albert Oriol

  219. Extramedullary plasmacytomas in the context of multiple myeloma

    Article • Advances in Therapy, November 2011, Springer Science + Business Media

    Dr Albert Oriol

  220. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

    Article • Blood, September 2011, American Society of Hematology

    Dr Albert Oriol

  221. Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study

    Article • Clinical Transplantation, August 2011, Wiley

    Dr Albert Oriol

  222. Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

    Article • Journal of Clinical Oncology, April 2011, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  223. Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia

    Article • Medicina Clínica, March 2011, Elsevier

    Dr Albert Oriol

  224. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients

    Article • International Journal of Hematology, March 2011, Springer Science + Business Media

    Dr Albert Oriol

  225. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

    Article • Leukemia, January 2011, Springer Science + Business Media

    Dr Albert Oriol

  226. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple mye...

    Article • The Lancet Oncology, October 2010, Elsevier

    Dr Albert Oriol

  227. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

    Article • Haematologica, July 2010, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  228. Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma

    Article • Clinical Cancer Research, June 2010, American Association for Cancer Research (AACR)

    Dr Albert Oriol

  229. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

    Article • Haematologica, February 2010, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  230. Metabolic fingerprinting of fresh lymphoma samples used to discriminate between follicular and diffuse large B-cell lymphomas

    Article • Experimental Hematology, November 2009, Elsevier

    Dr Albert Oriol

  231. Acute Lymphoblastic Leukemia in Adolescents and Young Adults

    Article • Hematology/Oncology Clinics of North America, October 2009, Elsevier

    Dr Albert Oriol

  232. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

    Article • Haematologica, October 2009, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  233. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy

    Article • Leukemia, December 2008, Springer Science + Business Media

    Josep Nomdedeu, Dr Albert Oriol

  234. High‐dose chemotherapy and immunotherapy in adult Burkitt lymphoma

    Article • Cancer, July 2008, Wiley

    Dr Albert Oriol

  235. Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96

    Article • Journal of Clinical Oncology, April 2008, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  236. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

    Article • Haematologica, April 2008, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  237. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma

    Article • Haematologica, February 2008, Ferrata Storti Foundation (Haematologica)

    Dr Albert Oriol

  238. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial

    Article • British Journal of Haematology, February 2008, Wiley

    Dr Albert Oriol

  239. Advanced Stage Is the Most Important Prognostic Factor for Survival in Patients with Systemic Acquired Immunodeficiency Syndrome-Related Non-Hodgkin's Lymphoma Treated with CHOP and Highly Active Antiretroviral Therapy

    Article • International Journal of Hematology, November 2007, Springer Science + Business Media

    Dr Albert Oriol

  240. Enterocolitis neutropénica en adultos con leucemia aguda o receptores de un trasplante de progenitores hematopoyéticos: estudio de 7 casos

    Article • Medicina Clínica, November 2007, Elsevier

    Dr Albert Oriol

  241. Phase II Pethema Trial of Alternating Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients With Multiple Myeloma: Efficacy and Clinical Implications of Tumor Response Kinetics

    Article • Journal of Clinical Oncology, October 2007, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  242. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: Two cases with a different outcome

    Article • American Journal of Hematology, September 2007, Wiley

    Dr Albert Oriol

  243. A step forward in therapy for ALL in infants

    Article • The Lancet, July 2007, Elsevier

    Dr Albert Oriol

  244. In Reply

    Article • Journal of Clinical Oncology, June 2007, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol

  245. In vivo quantification of response to treatment in patients with multiple myeloma by 1H magnetic resonance spectroscopy of bone marrow

    Article • Magnetic Resonance Materials in Physics Biology and Medicine, April 2007, Springer Science + Business Media

    Dr Albert Oriol

  246. Outcome and Prognostic Factors in Patients with Hematologic Malignancies Admitted to the Intensive Care Unit: A Single-Center Experience

    Article • International Journal of Hematology, April 2007, Springer Science + Business Media

    Dr Albert Oriol

  247. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia

    Article • European Journal Of Haematology, November 2006, Wiley

    Dr Albert Oriol

  248. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

    Article • Blood, October 2006, American Society of Hematology

    Dr Albert Oriol

  249. Comparison of Intensive Chemotherapy, Allogeneic, or Autologous Stem-Cell Transplantation As Postremission Treatment for Children With Very High Risk Acute Lymphoblastic Leukemia: PETHEMA ALL-93 Trial

    Article • Journal of Clinical Oncology, January 2006, American Society of Clinical Oncology (ASCO)

    Dr Albert Oriol, Jose Maria Guinea de Castro

  250. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia

    Article • Cancer, January 2006, Wiley

    Dr Albert Oriol

  251. Significado pronóstico de los subtipos inmunológicos de la leucemia aguda linfoblástica T del adulto. Estudio de 81 pacientes

    Article • Medicina Clínica, January 2006, Elsevier

    Dr Albert Oriol

  252. Complicaciones neurológicas después de un trasplante de progenitores hemopoyéticos. Estudio de 14 pacientes

    Article • Medicina Clínica, November 2005, Elsevier

    Dr Albert Oriol

  253. Serum Pepsinogen I: An Early Marker of Pernicious Anemia in Patients with Type 1 Diabetes

    Article • The Journal of Clinical Endocrinology & Metabolism, September 2005, Endocrine Society

    Dr Albert Oriol

  254. Prevalencia y significado pronóstico de los marcadores mieloides en adultos con leucemia aguda linfoblástica de alto riesgo

    Article • Medicina Clínica, September 2005, Elsevier

    Dr Albert Oriol

  255. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients

    Article • Leukemia & Lymphoma, January 2005, Taylor & Francis

    Dr Albert Oriol

  256. Evaluation of two replacement regimens in primary adrenal insufficiency patients. Effect on clinical symptoms, health-related quality of life and biochemical parameters

    Article • Journal of Endocrinological Investigation, May 2004, Springer Science + Business Media

    Dr Albert Oriol

  257. Nonconvulsive status epilepticus associated with cefepime in a patient undergoing autologous stem cell transplantation

    Article • Bone Marrow Transplantation, January 2004, Nature

    Dr Albert Oriol

  258. Causas por las que no se realiza el trasplante de progenitores hematopoyéticos en pacientes remitidos a una unidad de trasplante

    Article • Medicina Clínica, October 2003, Elsevier

    Dr Albert Oriol

  259. Improved Outcome of AIDS-Related Lymphoma in Patients With Virologic Response to Highly Active Antiretroviral Therapy

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, March 2003, Wolters Kluwer Health

    Dr Albert Oriol

  260. Causas por las que no se realiza el trasplante de progenitores hematopoyéticos en pacientes remitidos a una unidad de trasplante

    Article • Medicina Clínica, January 2003, Elsevier

    Dr Albert Oriol

  261. Bone Marrow Changes in Anorexia Nervosa Are Correlated With the Amount of Weight Loss and Not With Other Clinical Findings

    Article • American Journal of Clinical Pathology, October 2002, Oxford University Press (OUP)

    Dr Albert Oriol

  262. Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease

    Article • AIDS, September 2002, Wolters Kluwer Health

    Dr Albert Oriol

  263. Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia

    Article • British Journal of Haematology, August 2002, Wiley

    Dr Albert Oriol

  264. Favorable Impact of Virological Response to Highly Active Antiretroviral Therapy on Survival in Patients with AIDS-related Lymphoma

    Article • Leukemia & Lymphoma, January 2002, Taylor & Francis

    Dr Albert Oriol

  265. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone

    Article • British Journal of Haematology, March 2001, Wiley

    Dr Albert Oriol

  266. Bacteriemia por Lactobacillus spp. en un paciente con neutropenia secundaria al tratamiento de una leucemia aguda

    Article • Medicina Clínica, January 2001, Elsevier

    Dr Albert Oriol

  267. Neumonías en pacientes con leucemia linfática crónica. Estudio de 30 episodios

    Article • Medicina Clínica, January 2001, Elsevier

    Dr Albert Oriol

  268. Usefulness and Reproducibility of Cytomorphologic Evaluations to Differentiate Myeloma From Monoclonal Gammopathies of Unknown Significance

    Article • American Journal of Clinical Pathology, January 2001, Oxford University Press (OUP)

    Dr Albert Oriol

  269. Increased serum levels of CD44s and CD44v6 in patients with AIDS-related non-Hodgkin's lymphoma

    Article • AIDS, July 2000, Wolters Kluwer Health

    Dr Albert Oriol

  270. Saccharomyces cervisiae septicemia in septicemia in a patient with myelodsplastic syndrome

    Article • American Journal of Hematology, August 1993, Wiley

    Dr Albert Oriol

  271. Invasive aspergillosis in a patient with idiopathic thrombocytopenic purpura without underlying lung disease.

    Article • Thorax, April 1992, BMJ

    Dr Albert Oriol